Title : Randomized Multicenter Evaluation of Quality of Life and Treatment Satisfaction in Type 2 Diabetes Patients Receiving Once-Weekly Trelagliptin Versus a Daily Dipeptidyl Peptidase-4 Inhibitor.

Pub. Date : 2019 Aug

PMID : 31214997






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Analysis of the DTR-QOL and DTSQ results by subscales and stratification generally showed a numerical improvement with trelagliptin over daily DPP-4 inhibitors. trelagliptin dipeptidyl peptidase 4 Homo sapiens